

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

ANNOUNCEMENT

**PROPOSED ISSUANCE OF CORPORATE BONDS
AND
CHANGE IN USE OF PROCEEDS**

PROPOSED ISSUANCE OF CORPORATE BONDS

On 30 June 2022, the Board (the "Board") of the Company (the "Company") (the "Proposed Issuance" of Corporate Bonds (the "Corporate Bonds") in the PRC), pursuant to the resolution of the EGM (the "EGM") held on 23 June 2022, has announced its intention to propose the issuance of Corporate Bonds in the PRC.

1. ISSUE SIZE

The proposed issuance of Corporate Bonds in the PRC has a total issue size of B1,000,000,000 (one billion RMB) (the "B1,000,000,000").

2. TARGET SUBSCRIBERS

B. /

3. TERM

B. / ()

4. USE OF PROCEEDS

(**Proceeds**) B. /

5. INTEREST RATE

B. / B. /

6. VALIDITY OF THE RESOLUTION(S)

() / 24 () B. /

Reasons and benefits of the Proposed Issuance

B. / B. /

PROPOSED CHANGE IN USE OF PROCEEDS

Use of Proceeds

() 24 2020 ()
Prospectus— B
 (**Net Proceeds**—) B3,538.4
 2020 (**Global Offering**—)
 () 30
 2022 (**Interim Report**—) 30
 2022

A
 30% (B1,061.5)
 30% (B1,061.5)

 20%
 (B707.7)
 20% (B707.7)

A
 B1,115.2
 30 2022
 B2,423.2

Proposed Change in Use of Proceeds

本公司擬將招股說明書中披露的淨募資用途作如下修訂，以符合本集團業務發展的需要。有關修訂詳情請參閱招股說明書第B.1節「(Proposed Change in Use of Proceeds)」。除另有說明外，本招股說明書中所有金額均以人民幣百萬元為單位。

Business objectives	Original planned use of the Net Proceeds as disclosed in the Prospects (RMB million)	Utilised as at the date of this announcement (RMB million)	Remaining proceeds as at the date of this announcement (RMB million)	Revised allocation of unutilised Net Proceeds (RMB million)	Expected date of full utilisation of the unutilised Net Proceeds
(1) 收購及發展位於廣東省肇慶市端州區、江門新會區及江門蓬江區的土地，以興建及發展住宅發展項目	1,061.5 (30% of the net proceeds)	1,034.4	27.1		2024年
(2) 收購及發展位於廣東省肇慶市端州區、江門新會區及江門蓬江區的土地，以興建及發展住宅發展項目	1,061.5 (30% of the net proceeds)		1,061.5	636.9	2024年
(3) 收購及發展位於廣東省肇慶市端州區、江門新會區及江門蓬江區的土地，以興建及發展住宅發展項目	707.7 (20% of the net proceeds)		707.7	451.8	2024年
(4) 收購及發展位於廣東省肇慶市端州區、江門新會區及江門蓬江區的土地，以興建及發展住宅發展項目	707.7 (20% of the net proceeds)	80.8	626.9	376.2	2024年
(5) 收購及發展位於廣東省肇慶市端州區、江門新會區及江門蓬江區的土地，以興建及發展住宅發展項目				958.3	2024年
合計	3,538.4	1,115.2	2,423.2	2,423.2	

Reasons for and benefits of the Proposed Change in Use of Proceeds

... -19 ... 2022 ... B ...

A ... B ... 0.5 ... 0.5 ... 0.5 ...

B
B
24
A
B376.2

-19,
2021 / 2022
2022 / 31

A

A

B

B
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

30 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.

** for identification purposes only*